| scholarly article | Q13442814 |
| P50 | author | Kenneth H Eckels | Q92093916 |
| Veerachai Watanaveeradej | Q92093925 | ||
| P2093 | author name string | Richard G Jarman | |
| Robert V Gibbons | |||
| Sriluck Simasathien | |||
| Stephen J Thomas | |||
| Philippe Moris | |||
| Jeffrey R Currier | |||
| Bruce L Innis | |||
| Ines O Esquilin | |||
| Peifang Sun | |||
| Heather Friberg | |||
| Kristen M Bauer | |||
| P2860 | cites work | Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial | Q53826203 |
| Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015¹. Safety of CYD-TDV dengue vaccine | Q85952292 | ||
| The global distribution and burden of dengue | Q24628768 | ||
| Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children | Q26314710 | ||
| Mouse models to study dengue virus immunology and pathogenesis | Q27010151 | ||
| Vaccine-mediated immunity against dengue and the potential for long-term protection against disease | Q27014663 | ||
| The global burden of dengue: an analysis from the Global Burden of Disease Study 2013 | Q28388682 | ||
| Prevention and control of dengue-the light at the end of the tunnel | Q28729782 | ||
| Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies | Q30376727 | ||
| Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. | Q30387842 | ||
| DHIM supporting immunologic investigations and the identification of immune correlates of protection | Q33676842 | ||
| Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States | Q33773563 | ||
| Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial | Q33841045 | ||
| Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections | Q33959381 | ||
| Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. | Q34165624 | ||
| CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination | Q34234563 | ||
| Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans | Q34345965 | ||
| Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies | Q34351011 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. | Q34518791 | ||
| The global economic burden of dengue: a systematic analysis | Q34522607 | ||
| Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity | Q34722528 | ||
| Intracellular Cytokine Production by Dengue Virus–specific T cells Correlates with Subclinical Secondary Infection | Q34754885 | ||
| The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes | Q34992520 | ||
| H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. | Q35094040 | ||
| Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants | Q35131443 | ||
| Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. | Q35645556 | ||
| Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia | Q35856554 | ||
| A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico | Q36026204 | ||
| The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response | Q36031220 | ||
| CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate | Q36208591 | ||
| A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults | Q36523070 | ||
| Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells | Q36895622 | ||
| Optimizing peptide matrices for identifying T-cell antigens | Q36982384 | ||
| Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection | Q38087545 | ||
| Identifying protective dengue vaccines: Guide to mastering an empirical process | Q38125045 | ||
| Analysis of cell-mediated immune responses in support of dengue vaccine development efforts | Q38605194 | ||
| Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward | Q38609515 | ||
| Immune correlates of protection for dengue: State of the art and research agenda | Q38652971 | ||
| Immunopathogenesis Versus Protection in Dengue Virus Infections | Q39410861 | ||
| Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development | Q39521661 | ||
| Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness | Q40039507 | ||
| Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate | Q40318917 | ||
| Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects | Q40410592 | ||
| Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. | Q40424733 | ||
| Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | Q40536052 | ||
| Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. | Q40541524 | ||
| Quantitation of dengue virus specific CD4+ T cells by intracellular cytokine staining | Q40541753 | ||
| Use of overlapping peptide mixtures as antigens for cytokine flow cytometry | Q45112956 | ||
| Duration of humoral immunity to common viral and vaccine antigens | Q45872621 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P304 | page(s) | 2090-2105 | |
| P577 | publication date | 2019-04-15 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions | |
| P478 | volume | 15 |
| Q92001054 | Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine | cites work | P2860 |
Search more.